Lessons From Generic Launches: About The Study
Executive Summary
IMS Consulting Group studied 4,564 generic launches dating between July 1, 2005 and July 31, 2010, in order to gauge key criteria for success.
You may also be interested in...
Entering The Generics Business In Mature Markets: Lessons Learned From 4,500 Launches
In response to major market challenges, Big Pharmas have or are considering entering the small-molecule generics business. An IMS Consulting Group analysis of more than 4,500 generics launches between 2005 and 2010 tracks key attributes would-be branded company players need to know for success.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.